{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06138769","nct_id":"NCT06138769","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06138769. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Lenvatinib 12 mg (body weight 60 kg or greater) or 8 mg (body weight \\< 60 kg) once orally every day","label":"Lenvatinib","type":"EXPERIMENTAL"}],"collaborators":["Eisai Inc.","Chonnam National University Hospital","Seoul National University","Gangneung Asan Hospital","Ulsan University Hospital","Chosun University Hospital","Dong-A University Hospital","Bundang CHA Hospital","Seoul National University Bundang Hospital","Yonsei University","Hanyang University Seoul Hospital","Chungnam National University Hospital","Saint Vincent's Hospital, Korea","Gyeongsang National University Hospital","Ewha Womans University","Chungbuk National University Hospital","Severance Hospital","Gachon University Gil Medical Center","The Catholic University of Korea","Bucheon St. Mary's Hospital"],"completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":50,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Lenvatinib","otherNames":[],"type":"DRUG"}],"last_update":"2024-07-03","lead_sponsor":"Asan Medical Center","official_title":"Multicenter Phase 2 Trial of Lenvatinib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Atezolizumab Plus Bevacizumab","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"1 year"}],"references":[{"citation":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.","pmid":"29433850","type":"BACKGROUND"},{"citation":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.","pmid":"32402160","type":"BACKGROUND"},{"citation":"Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308. No abstract available.","pmid":"30285213","type":"BACKGROUND"},{"citation":"Kim HD, Sym SJ, Chon HJ, Kim M, Kang JH, Ryoo BY, Lee CK, Hong J, Ryu H, Bae WK, Kim H, Kim H, Kim JW, Kim TY, Yoo C. Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. J Hepatol. 2026 Feb;84(2):308-315. doi: 10.1016/j.jhep.2025.08.020. Epub 2025 Sep 4.","pmid":"41038766","type":"DERIVED"}],"start_date":{"date":"2023-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma","url":"https://clinicaltrials.gov/study/NCT06138769"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06138769"}